Methods for treating subjects suffering from acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles
AssigneesUniversity of Cincinnati, The University of Chicago, The Board of Trustees of the University of Illinois
InventorsJianjun Chen, Seungpyo Hong, Xi Jiang, Zejuan Li
Life of this patent
Estimating the term…
Abstract
A nanoparticle delivery system designed for sustained delivery of microRNA-150 (miR-150) to FLT3-overexpressing acute myeloid leukemia (AML) cells, the delivery system comprising poly(amidoamine) (PAMAM) dendrimers complexed with miR-150, wherein at least one dendrimer is surface-functionalized with a ligand specific for FLT3 receptor, and methods for treating AML characterized by FLT3-overexpression are provided.
Claims16
A method of treating acute myeloid leukemia (AML) in a patient in need thereof, the method comprising:
- administering to the patient an FLT3-guided dendrimeric nanoparticle complexed with miR-150, wherein the FLT3-guided dendrimeric nanoparticle comprises a PAMAM dendrimer that is surface-functionalized with a ligand specific for FLT3 receptor, said ligand consists of a natural and/or synthetic FLT3L peptide having at least 90% sequence homology to SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.